Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023
June 29 2023 - 4:01PM
Regeneron Pharmaceuticals, Inc. (NASDAQ:
REGN)
today announced that it will report its second quarter 2023
financial and operating results on Thursday, August 3, 2023, before
the U.S. financial markets open. The Company will host a conference
call and simultaneous webcast at 8:30 AM Eastern Time that day.
Conference Call Information
Participants may access the conference call live via webcast on the
’Investors and Media’ page of Regeneron’s website at
https://investor.regeneron.com. To participate via telephone,
please register in advance at this link. Upon registration, all
telephone participants will receive a confirmation email detailing
how to join the conference call, including the dial-in number along
with a unique passcode and registrant ID that can be used to access
the call. A replay of the conference call and webcast will be
archived on the Company’s website for at least 30 days.
About Regeneron Regeneron
(NASDAQ: REGN) is a leading biotechnology company that invents,
develops and commercializes life-transforming medicines for people
with serious diseases. Founded and led for 35 years by
physician-scientists, our unique ability to repeatedly and
consistently translate science into medicine has led to nine
FDA-approved treatments and numerous product candidates in
development, almost all of which were homegrown in our
laboratories. Our medicines and pipeline are designed to help
patients with eye diseases, allergic and inflammatory diseases,
cancer, cardiovascular and metabolic diseases, pain, hematologic
conditions, infectious diseases and rare diseases.
Regeneron is accelerating and improving the
traditional drug development process through our proprietary
VelociSuite® technologies, such as VelocImmune®, which uses unique
genetically humanized mice to produce optimized fully human
antibodies and bispecific antibodies, and through ambitious
research initiatives such as the Regeneron Genetics Center, which
is conducting one of the largest genetics sequencing efforts in the
world.
For more information, please visit
www.Regeneron.com or follow @Regeneron on Twitter.
Contact Information: Investor
Relations Ryan Crowe 914.847.8790 ryan.crowe@regeneron.com
Corporate Communications Christina Chan
914.847.8827 christina.chan@regeneron.com
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024